| |
 |
 |
 |
 |
 |
 |
 |
May 24, 2006
A Japanese Medical-Use Patent is Granted for NFκB Decoy Oligonucleotide
-Covering Treatment for Atopic Dermatitis- |
 |
|
|
AnGes MG, Inc. is pleased to announce that a medical-use patent for NFκB decoy
covering the treatment of atopic dermatitis has been granted in Japan (JP3778357).
The patent covers a broad range of transdermal external medications of NFκB
decoy and also “compositions” including NFκB decoy for the treatment of atopic
dermatitis. The patent provides powerful support to the project currently being
developed in collaboration with Alfresa Pharma Corporation.
AnGes MG has already filed patent applications for treatment for atopic dermatitis in
the US and Europe in addition to Japan to cover global development activities.
Besides this patent, AnGes MG aims to establish intellectual property rights in line
with the expansion of clinical indications by filing additional applications for use of
NFκB decoy oligonucleotide in other diseases, including asthma, aneurysms, organ
and vascular transplantation, psoriasis, and rheumatoid arthritis. A patent has
already been granted (JP3474879) for use in the treatment of reperfusion disorder;
postoperative aggravation from organ transplantations and surgery; post PTCA
restenosis; cancer metastasis/invasion and cachexia.
AnGes MG is currently conducting phase I clinical trial of NFκB decoy
oligonucleotide for atopic dermatitis. Patient registration has already been
completed, and we are currently in the process of analyzing the results. |
|
|
